People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Checkmate Pharmaceuticals, Inc. | — | Biotechnology | Series C | $185.1M | $3.5B | 2019 |
| Xcellerex, Inc. | — | Other | Seed | $2.0M | $36.4M | 2011 |
Jon Lieber at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jon Lieber on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Robert Weisskoff | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Joseph Zakrzewski | 1 | 6 |
| Keith Flaherty | 1 | 5 |
| Alan Fuhrman | 1 | 5 |
| Peter Colabuono | 1 | 4 |
| David J. Williams | 1 | 3 |
| Guy Broadbent | 1 | 3 |
| KLEEM CHAUDHARY | 1 | 2 |
| Michael M Powell | 1 | 2 |
| Michael A. Powell | 1 | 2 |
| Jonathan Lieber | 1 | 2 |
| Arthur M. Krieg | 1 | 2 |
| David Mauro | 1 | 2 |
| Thomas Monath | 1 | 2 |
| Scot Galliher | 1 | 1 |
| Boris Lipkin | 1 | 1 |
| Douglas J. Treco | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.